Cover Image

Effects of secukinumab on serum adipocytokines: preliminary data

A. Fassio, D. Gatti, P. Gisondi, G. Girolomoni, O. Viapiana, A. Giollo, M. Zamboni, M. Rossini, L. Idolazzi
  • D. Gatti
    Unit of Rheumatology, University of Verona, Italy
  • P. Gisondi
    Unit of Dermatology, University of Verona, Italy
  • G. Girolomoni
    Unit of Dermatology, University of Verona, Italy
  • O. Viapiana
    Unit of Rheumatology, University of Verona, Italy
  • A. Giollo
    Unit of Rheumatology, University of Verona, Italy
  • M. Zamboni
    Unit of Geriatrics, University of Verona, Italy
  • M. Rossini
    Unit of Rheumatology, University of Verona, Italy
  • L. Idolazzi
    Unit of Rheumatology, University of Verona, Italy

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, connective tissues and the axial skeleton. Metabolic syndrome is an independent risk factor for psoriasis (Pso) development and is associated with more severe forms of Pso. Adipocytokines are secreted by white adipose tissue and are thought to link obesity with the development of metabolic and cardiovascular diseases. Secukinumab is a new monoclonal antibody with a different mechanism of action. This antibody selectively binds to and neutralizes interleukin-17 (IL-17) and it has shown efficacy in the treatment of PsA. The aim of this study was to evaluate the possible interferences of secukinumab on different adipocytokines. We enrolled 28 patients with PsA, classified with the CASPAR criteria. Serum samples were stored at baseline and then at the first, the third and the sixth month of therapy. Resistin, chemerin, adiponectin and C-reactive protein (CRP) were dosed. When tested globally, none of the adipokine tested showed any statistically significant variation. However, when the male group was tested, both resistin and chemerin at M6 showed a significant decrease from baseline. CRP did not show any variation at any time point. Our study demonstrated that treatment with secukinumab has little influence on the levels of adipokines tested within the first six months of treatment even though it might exert different influence between males and females from a metabolic perspective. Further studies with greater numbers of patients are needed to determine whether these preliminary results have clinical relevance.

Keywords

Psoriasis; psoriatic arthritis; secukinumab; adipokines; resistin; adiponectin; chemerin.

Full Text:

PDF
Submitted: 2016-12-11 12:48:21
Published: 2017-09-21 12:06:24
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
798

Views:
PDF
263

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 A. Fassio, D. Gatti, P. Gisondi, G. Girolomoni, O. Viapiana, A. Giollo, M. Zamboni, M. Rossini, L. Idolazzi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185